

Diane Damotte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10578151/publications.pdf>

Version: 2024-02-01

106
papers

10,590
citations

46984

47
h-index

36008

97
g-index

113
all docs

113
docs citations

113
times ranked

15830
citing authors

#	ARTICLE	IF	CITATIONS
1	Positron Emission Tomographyâ€“Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1091-1101.	0.8	11
2	Twenty-Year Survival of Patients Operated on for Non-Small-Cell Lung Cancer: The Impact of Tumor Stage and Patient-Related Parameters. <i>Cancers</i> , 2022, 14, 874.	1.7	4
3	Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients. <i>Lung Cancer</i> , 2022, 166, 221-227.	0.9	8
4	SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils. <i>Lung Cancer</i> , 2022, 169, 13-21.	0.9	9
5	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	0.6	60
6	CXCR6 deficiency impairs cancer vaccine efficacy and CD8⁺ resident memory T-cell recruitment in head and neck and lung tumors. , 2021, 9, e001948.		41
7	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 626776.	2.2	39
8	New Therapeutic Strategies for Lung Cancer. <i>Cancers</i> , 2021, 13, 1937.	1.7	5
9	Surgical Diagnosis of Malignant Pleural Mesothelioma: 20 Yearsâ€™ Experience at a High-Volume Referral Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 1973.	1.0	0
10	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. <i>Cancer Immunology Research</i> , 2021, 9, 891-908.	1.6	43
11	Size and Predictive Factors of Microscopic Tumor Extension in Locally Advanced Non-Small Cell Lung Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 491-501.	1.1	1
12	Metabolic features of cancer cells impact immunosurveillance. , 2021, 9, e002362.		11
13	ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, e686-e690.	1.1	6
14	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	2.7	6
15	CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNÎ³ and ICAM-1. <i>Cancer Immunology Research</i> , 2021, 9, 1425-1438.	1.6	31
16	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	2.3	16
17	Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. , 2020, 8, e001054.		54
18	Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer. <i>Cancers</i> , 2020, 12, 2882.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. <i>Scientific Reports</i> , 2020, 10, 16641.	1.6	10
20	Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 587-595.	1.0	5
21	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 497-505.	1.1	7
22	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , 2020, 4, 2523-2535.	2.5	32
23	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	0.5	40
24	PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093797.	1.4	19
25	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	1.7	72
26	Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage. <i>Cancers</i> , 2020, 12, 266.	1.7	37
27	Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study). <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13299-13305.	1.0	1
28	Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. <i>Cancer Letters</i> , 2019, 464, 5-14.	3.2	148
29	Clinical Characteristics, Molecular Phenotyping, and Management of Isolated Adrenal Metastases From Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 405-411.	1.1	9
30	Unexpected pulmonary tumour in a young woman. <i>Journal of Clinical Pathology</i> , 2019, 72, 783-783.	1.0	1
31	The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. <i>Journal of Translational Medicine</i> , 2019, 17, 357.	1.8	88
32	PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2019, 18, 3471-3480.	0.8	10
33	Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. , 2019, 7, 121.		71
34	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2019, 8, e1581556.	2.1	68
35	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 844-856.	0.5	55
36	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, S89-S101.	0.6	52

#	ARTICLE	IF	CITATIONS
37	Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1053-1059.	0.7	21
38	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 341-351.	2.1	61
39	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. <i>EBioMedicine</i> , 2019, 48, 191-202.	2.7	55
40	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	1.7	28
41	Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells. <i>Oncolmmunology</i> , 2019, 8, e1505174.	2.1	37
42	Mutational Landscape of Grey Zone Lymphoma. <i>Blood</i> , 2019, 134, 21-21.	0.6	3
43	Prednisone, Vinblastine, Doxorubicin and Bendamustine (PVAB) Regimen in First Line Therapy for Older Patients with Advanced-Stage Classical Hodgkin Lymphoma: Results of a Prospective Multicenter Phase II Trial of the Lymphoma Study Association (LYSA). <i>Blood</i> , 2019, 134, 2832-2832.	0.6	5
44	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 928-940.	2.5	62
45	Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4041-E4050.	3.3	564
46	Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. <i>Oncolmmunology</i> , 2018, 7, e1423184.	2.1	38
47	Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells. <i>Oncotarget</i> , 2018, 9, 9088-9099.	0.8	29
48	<i>TP53</i> , <i>STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.	3.2	257
49	Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. <i>Haematologica</i> , 2017, 102, 150-159.	1.7	61
50	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1601873.	3.1	38
51	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66
52	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. <i>Lung Cancer</i> , 2017, 113, 93-101.	0.9	38
53	Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study- The Importance of Pathological N Status, More Than We Thought. <i>Lung</i> , 2017, 195, 789-798.	1.4	31
54	Thoracic Endometriosis Syndrome Other Than Pneumothorax: Clinical and Pathological Findings. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1865-1871.	0.7	30

#	ARTICLE	IF	CITATIONS
55	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. <i>Oncolmmunology</i> , 2017, 6, e1358330.	2.1	15
56	Body Mass Index and Total Psoas Area Affect Outcomes in Patients Undergoing Pneumonectomy for Cancer. <i>Annals of Thoracic Surgery</i> , 2017, 103, 287-295.	0.7	60
57	Ex Vivo&/em> Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	14
58	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 842-847.	1.2	13
59	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. <i>Oncotarget</i> , 2017, 8, 44960-44975.	0.8	82
60	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , 2017, 35, 2008-2017.	0.8	155
61	Different prognostic impact of <i>STK11</i> mutations in non-squamous non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 23831-23840.	0.8	67
62	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	2.0	79
63	Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1255394.	2.1	62
64	Correlation between radiological and pathological features of operated ground glass nodules. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 51, ezw294.	0.6	3
65	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. <i>Science Immunology</i> , 2016, 1, aaf6925.	5.6	142
66	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1403-1412.	2.5	48
67	Calreticulin Expression in Human Nonâ€Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016, 76, 1746-1756.	0.4	164
68	Estrogen Therapy Delays Autoimmune Diabetes and Promotes the Protective Efficiency of Natural Killer T-Cell Activation in Female Nonobese Diabetic Mice. <i>Endocrinology</i> , 2016, 157, 258-267.	1.4	22
69	mRNA expression levels and prognostic value of PD1/PDL1 and CTLA4 pathways genes in a large series of 155 bladder tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4523-4523.	0.8	0
70	Which is the Role of Pneumonectomy in the Era of Parenchymal-Sparing Procedures? Early/Long-Term Survival and Functional Results of a Single-Center Experience. <i>Lung</i> , 2015, 193, 965-973.	1.4	20
71	Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration. <i>Frontiers in Immunology</i> , 2015, 6, 500.	2.2	118
72	Epidemiology of spontaneous pneumothorax: gender-related differences. <i>Thorax</i> , 2015, 70, 653-658.	2.7	164

#	ARTICLE	IF	CITATIONS
73	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3031-3040.	3.2	355
74	A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4 ⁺ T cell receptor repertoire clonality. <i>Oncolmmunology</i> , 2015, 4, e1051922.	2.1	79
75	The Non-“Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 377-390.	2.5	204
76	Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells. <i>Cancer Research</i> , 2014, 74, 705-715.	0.4	466
77	The immune contexture of primary and metastatic human tumours. <i>Current Opinion in Immunology</i> , 2014, 27, 8-15.	2.4	137
78	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non-“Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 5008-5018.	0.4	83
79	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 832-844.	2.5	564
80	Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?. <i>Journal of Translational Medicine</i> , 2014, 12, 131.	1.8	22
81	Pneumothorax in Women of Child-Bearing Age. <i>Chest</i> , 2014, 145, 354-360.	0.4	56
82	The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status. <i>Chest</i> , 2014, 146, 633-643.	0.4	80
83	Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e106914.	1.1	137
84	Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib. <i>Oncotarget</i> , 2014, 5, 8252-8269.	0.8	49
85	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
86	Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 1305-1311.	0.4	21
87	Prognostic Significance of Vascular and Lymphatic Emboli in Resected Pulmonary Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2013, 95, 1204-1210.	0.7	28
88	Prognostic value of LIPC in non-small cell lung carcinoma. <i>Cell Cycle</i> , 2013, 12, 543-543.	1.3	1
89	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. <i>Clinical Cancer Research</i> , 2013, 19, 4079-4091.	3.2	301
90	Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. <i>Journal of Clinical Investigation</i> , 2012, 122, 899-910.	3.9	763

#	ARTICLE	IF	CITATIONS
91	Characterization of Chemokines and Adhesion Molecules Associated with T cell Presence in Tertiary Lymphoid Structures in Human Lung Cancer. <i>Cancer Research</i> , 2011, 71, 6391-6399.	0.4	245
92	Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors. <i>PLoS ONE</i> , 2011, 6, e17621.	1.1	81
93	Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1161-1167.	0.4	64
94	Pneumothorax Recurrence After Surgery in Women: Clinicopathologic Characteristics and Management. <i>Annals of Thoracic Surgery</i> , 2011, 92, 322-326.	0.7	47
95	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 13-25.	2.7	95
96	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. <i>Cancer Research</i> , 2011, 71, 5412-5422.	0.4	404
97	CD4+CD25+ T Cells Play a Complex Role in the Pediatric Combined Liver-Intestinal Graft Acceptance. <i>Transplantation</i> , 2010, 90, 95-97.	0.5	3
98	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 1-24.	0.7	193
99	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1285-1297.	3.9	191
100	Study of the Impact of Liver Transplantation on the Outcome of Intestinal Grafts in Children. <i>Transplantation</i> , 2006, 81, 992-997.	0.5	28
101	Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2654-2666.	13.9	1,860
102	An Interval Tightly Linked to but Distinct From the H2 Complex Controls Both Overt Diabetes (Idd16) and Chronic Experimental Autoimmune Thyroiditis (Ceat1) in Nonobese Diabetic Mice. <i>Diabetes</i> , 2002, 51, 2141-2147.	0.3	30
103	IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not for FasL-induced immune deviation. <i>European Journal of Immunology</i> , 2002, 32, 1292.	1.6	12
104	Up-to-date evolution of small bowel transplantation in children with intestinal failure. <i>Journal of Pediatric Surgery</i> , 1999, 34, 841-844.	0.8	37
105	Pathology of intestinal transplantation. <i>Current Opinion in Organ Transplantation</i> , 1999, 4, 355.	0.8	3
106	Analysis of susceptibility of NOD mice to spontaneous and experimentally induced thyroiditis. <i>European Journal of Immunology</i> , 1997, 27, 2854-2862.	1.6	67